´ëÀüÀ»Áö´ëÇк´¿ø Á¦ 1 ȸ ´ëÇÑôÃß¿Ü°úÇÐȸ, Áߺΰñ´Ù°øÁõÇÐȸ ¿¬¼ö°Á : 2019-06-16±³À°ÀÏÀÚ : 2019-06-16
±³À°Àå¼Ò : ´ëÀüÀ»Áö´ëÇк´¿ø ¹ü¼®È¦
±³À°ÁÖÁ¦ :
Á¦ 1 ȸ ´ëÇÑôÃß¿Ü°úÇÐȸ, Áߺΰñ´Ù°øÁõÇÐȸ ¿¬¼ö°ÁÂÁÖÃÖ±â°ü : ´ëÇÑôÃß¿Ü°úÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÀü.ÃæûÁöȸ
´ã´çÀÚ : À̼ö¹Î
¿¬¶ôó : 02-483-3413
À̸ÞÀÏ :
bmd2019@naver.com ±³À°Á¾·ù : Á¤Çü¿Ü°ú
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 4Á¡
Áö¿ª :
´ëÀü±¤¿ª½Ã±³À°½Ã°£ : 5 ½Ã°£ 30ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í »çÀüµî·Ï 1 ¸¸¿ø , ÇöÀåµî·Ï 2¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 10:00~10:20 BMD Çؼ®¹ý ¹× °Ë»çÀÇ ¿À·ù ÀÌÇö½Â(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 10:20~10:40 ȯÀÚ ¸ÂÃãÇü °ñ´Ù°øÁõ ¾à¹° ¼±ÅÃÇϱâ Àӹ̰æ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 10:40~11:00 Çѱ¹ÀÎÀÇ VitD ¼·Ãë ÇöȲ°ú °ñ´Ù°øÁõ À̼±¿µ(Ãæ³²´ë)
Åä·Ð 06-16 3Ãþ¹ü¼®È¦ 11:00~11:10 Q&A ()
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 11:10~11:30 Denosumab as a primary therapy È«ÁØȸ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 11:30~11:50 Deily and weekly Teriparatide ±è»ó¹ü(Ãæ³²´ëÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 11:50~12:10 BP resistant and intolerabie patients ÀÌÀ¯¹Ì(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 12:10~12:30 ¼ö¼ú ÀüÈÄÀÇ °ñ´Ù°øÁõ Ä¡·áÁ¦, ¾ðÁ¦ Áß´Ü, ¾ðÁ¦ ½ÃÀÛ ±è¿µÀ²(°¡Å縯ÀÇ´ë)
Åä·Ð 06-16 3Ãþ¹ü¼®È¦ 12:30~12:40 Q&A ()
½Ä»ç 06-16 3Ãþ¹ü¼®È¦ 12:40~01:10 Á¡½É½Ã°£ ()
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 01:10~01:30 SarcopeniaÀÇ Áø´Ü ±è±¤ÁØ(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 01:30~01:50 Sarcopenia Drug development À̱¤Ç¥(Çѱ¹»ý¸í°øÇבּ¸È¸)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 01:50~02:10 Sarcopenia and exercise intevention ¼Û¿í(¼¿ï´ë)
Åä·Ð 06-16 3Ãþ¹ü¼®È¦ 02:10~02:20 Q&A ()
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 02:20~02:40 Atypical femur fractureÀÇ ¼ö¼úÀû Ä¡·á Â÷¿ëÇÑ(À»ÁöÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 02:40~03:00 ¾à¹° °ü·Ã ¾à°ñ ±«»çÁõ (MRONJ)Ä¡·á¹ý°ú ¿¹ÈÄ ±èÁø¿ì(ÀÌ´ë¸ñµ¿º´¿ø)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 03:00~03:20 2019 °ñ´Ù°øÁõ °Ë»ç ¹× Ä¡·áÁ¦ÀÇ ÃֽŠº¸Çè ±è¹üÅÃ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 06-16 3Ãþ¹ü¼®È¦ 03:20~03:50 °ñ´Ù°øÁõ °ü·Ã »è°¨ ÇÇÇÏ´Â ¹æ¹ä À±¼®±â(õ¾È¿£µµ³»°ú)
Åä·Ð 06-16 3Ãþ¹ü¼®È¦ 03:50~04:00 Q&A ()